C-Reactive Protein, Interleukin-6, Trimethylamine-N-Oxide, Syndecan-1, Nitric Oxide, and Tumor Necrosis Factor Receptor-1 in Heart Failure with Preserved Versus Reduced Ejection Fraction: a Meta-Analysis-Reference-Cited by-同舟云学术

C-Reactive Protein, Interleukin-6, Trimethylamine-N-Oxide, Syndecan-1, Nitric Oxide, and Tumor Necrosis Factor Receptor-1 in Heart Failure with Preserved Versus Reduced Ejection Fraction: a Meta-Analysis

Published:2022-12-07 Issue:1 Volume:20 Page:1-11
ISSN:1546-9530
Container-title:Current Heart Failure Reports
language:en
Short-container-title:Curr Heart Fail Rep

Author:

Gui Xi Yao,Rabkin Simon W.

Publisher

Springer Science and Business Media LLC

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine,Emergency Medicine

Link

https://link.springer.com/content/pdf/10.1007/s11897-022-00584-9.pdf

Reference58 articles.

1. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6:606–19. https://doi.org/10.1161/HHF.0b013e318291329a.

2. Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation. 2012;126:65–75. https://doi.org/10.1161/CIRCULATIONAHA.111.080770.

3. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of Amer. Circ (New York, NY). 2017;136:e137–61. https://doi.org/10.1161/cir.0000000000000509.

4. Shah S. Precision medicine for heart failure with preserved ejection fraction: an overview. J Cardiovasc Transl Res. 2017;10:233–44. https://doi.org/10.1007/s12265-017-9756-y.

5. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451–61. https://doi.org/10.1056/NEJMoa2107038.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Venous Thrombosis and Thromboembolism of Pulmonary Artery in Plastic Surgery: Risk Factors, Course Options and Therapeutic Strategies;Bulletin of Science and Practice;2024-02-15

2. Renin–angiotensin–aldosterone system inhibitors in the heart failure management;Pathophysiology, Risk Factors, and Management of Chronic Heart Failure;2024

3. Prognostic value of soluble biomarkers of haemodynamic stress, inflammation and fibrosis in hfpef: a retrospective cohort study;Russian Cardiology Bulletin;2024

4. Myeloperoxidase, carnitine, and derivatives of reactive oxidative metabolites in heart failure with preserved versus reduced ejection fraction: A meta-analysis;International Journal of Cardiology;2023-12

5. Soluble guanylate cyclase (sGC) stimulators in heart failure with preserved ejection fraction: a systematic review and meta-analysis;Shock;2023-11-22